Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CHRM1 | P11229 | 1/20 | 0.52 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.51 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.49 |
| ▸ | SCN9A | Q15858 | 1/20 | 0.48 |
| ▸ | HRH2 | P25021 | 1/20 | 0.48 |
| ▸ | HRH1 | P35367 | 1/20 | 0.48 |
| ▸ | CYP3A4 | P08684 | 6/20 | 0.47 |
| ▸ | CYP3A5 | P20815 | 1/20 | 0.46 |
| ▸ | PABPC1 | P11940 | 1/20 | 0.46 |
| ▸ | FNTA | P49354 | 1/20 | 0.44 |
| ▸ | FNTB | P49356 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7390953 | 0.84 | PABPC1 (0.61) | KMT2AMAPK1HRH2HRH1PABPC1 | |
| SCHEMBL7390948 | 0.84 | PABPC1 (0.61) | KMT2AMAPK1HRH2HRH1PABPC1 | |
| SCHEMBL7556296 | 0.83 | KMT2A (0.62) | CHRM1KMT2AMAPK1SCN9AHRH2 | |
| SCHEMBL7556302 | 0.83 | KMT2A (0.62) | CHRM1KMT2AMAPK1SCN9AHRH2 | |
| SCHEMBL6161351 | 0.83 | KMT2A (0.57) | CHRM1KMT2AMAPK1SCN9AHRH2 | |
| SCHEMBL8305402 | 0.82 | KMT2A (0.52) | KMT2AMAPK1HRH2HRH1 | |
| SCHEMBL7594697 | 0.82 | CHRM1 (0.53) | CHRM1CYP3A4FNTAFNTB | |
| SCHEMBL6069699 | 0.82 | KMT2A (0.57) | KMT2ASCN9ACYP3A4 | |
| SCHEMBL6069703 | 0.82 | KMT2A (0.57) | KMT2ASCN9ACYP3A4 | |
| SCHEMBL5891895 | 0.81 | KMT2A (0.54) | CHRM1KMT2AMAPK1SCN9AHRH2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20020119979-A1 | Acyclic compounds and methods for treating multidrug resistance | PROCTER & GAMBLE COMPANY, THE | 2002-08-29 | — | — | US | disclosed |
| WO-2002032871-A2 | COMPOUNDS AND METHODS FOR TREATING MULTIDRUG RESISTANCE | THE PROCTER & GAMBLE COMPANY (US) | 2002-04-25 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020119979-A1 | Acyclic compounds and methods for treating multidrug resistance | ABCC1, ABCB1, ABCB11 | CHRM1 3787/4885KMT2A 3528/4885MAPK1 4085/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.